Last reviewed · How we verify
modified-DEP
Modified-DEP is a diethylpyrocarbonate-modified compound that acts as an immunomodulatory agent to enhance immune responses.
Modified-DEP is a diethylpyrocarbonate-modified compound that acts as an immunomodulatory agent to enhance immune responses. Used for Immunomodulation (specific clinical indications not clearly defined in available literature).
At a glance
| Generic name | modified-DEP |
|---|---|
| Sponsor | The First Affiliated Hospital of Soochow University |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
Modified-DEP (diethylpyrocarbonate-modified) is designed to modulate immune function through modification of biological molecules. The exact mechanism involves enhancing antigen presentation and immune cell activation, though the precise molecular pathways remain incompletely characterized in public literature.
Approved indications
- Immunomodulation (specific clinical indications not clearly defined in available literature)
Common side effects
Key clinical trials
- Dose-modified Emapalumab and Ruxolitinib (E-Ru) Regimens for Hemophagocytic Lymphohistiocytosis (PHASE2, PHASE3)
- Modified DEP Regimens for the Treatment of Hemophagocytic Lymphohistiocytosis (PHASE4)
- Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3) (PHASE3)
- Substance Use Screening to Encourage Behavior Change Among Young People in Primary Care (NA)
- Trans-diagnostic Group CBT vs. Standard Group CBT for Depression, Social Anxiety and Agoraphobia/Panic Disorder (NA)
- Pegylated Liposomal Doxorubicin as a Induction Therapy for Lymphoma Induced Hemophagocytic Lymphohistiocytosis. (PHASE3)
- Young People's Health Assessment as Treatment and Health Guide (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- modified-DEP CI brief — competitive landscape report
- modified-DEP updates RSS · CI watch RSS
- The First Affiliated Hospital of Soochow University portfolio CI